NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387

Reuters

06-04

<a href="https://laohu8.com/S/NNVC">NanoViricides Inc.</a> Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387

NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1035329) on June 04, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540050346"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540050346\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540050346?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 18:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540050346","market":"us","top_or_hot":-1,"title":"NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1035329) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-04 18:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1035329) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL47VQjN:1","article_id":"2540050346","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540050346","pubTimestamp":1749034520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","NNVC":"NanoViricides Inc.","BK4139":"生物科技"},"translate_title":"NanoViricides Inc.宣布即将对有前途的麻疹候选药物NV-387进行动物研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NNVC":0.9},"content_text":"NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387\n    \n\n        NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1035329) on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}